A comparison of propranolol and compound RO3-4787 in the treatment of arterial hypertension in man.
1. The effects of propranolol and RO3-4787, a new beta-adrenoceptor antagonist with a partial agonist activity, have been studied in a blind, cross-over comparison with placebo. 2. In ten patients who completed the study, the two drugs produced a similar reduction in blood pressure; the reduction in heart rate with propranolol was significantly (P less than 0.001) greater than that produced by RO3-4787. 3. Plasma renin activity averaged 4.13 +/- 1.37 ng h-1 ml-1 on placebo, fell to 3.64 +/- 1.47 ng h-1 ml-1 on propranolol and to 2.50 +/- 1.39 ng h-1 ml-1 on RO3-4787. 4. No correlation was demonstrable between the log plasma concentration of either propranolol or RO3-4787 and change in blood pressure.
D000328:Adult; D000368:Aged; D001572:Benzofurans / Q000097:blood / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D004983:Ethanolamines / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000097:blood / Q000627:therapeutic use*; D012083:Renin / Q000097:blood
D001572:Benzofurans; D004983:Ethanolamines; D011433:Propranolol; D012083:Renin